Nasdaq ikna.

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...

Nasdaq ikna. Things To Know About Nasdaq ikna.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)He focuses on private company investments and fundraising for the firm. Mr. Draetta currently serves on the board of Chord Therapeutics and is Chief Financial Officer of Omega Alpha SPAC (NASDAQ ...IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ...About Nasdaq Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients ...

3 mai 2022 ... Maude Tessier joins Seismic after serving as Chief Business Officer of Ikena Oncology (Nasdaq: IKNA), a clinical-stage biotech company, where ...Nov 7, 2023 · BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ... Ikena Oncology Stock Earnings. The value each IKNA share was expected to gain vs. the value that each IKNA share actually gained. Ikena Oncology ( IKNA) reported Q3 2023 earnings per share (EPS) of -$0.40, beating estimates of -$0.43 by 7.29%. In the same quarter last year, Ikena Oncology 's earnings per share (EPS) was -$0.48.

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it ...

BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...IKNA Price $1.40 Fair Value Price N/A Market Cap $67.56M 52 Week Low $1.02 52 Week High $7.64 P/E -0.86x P/B 0.43x P/S 13.48x PEG N/A Dividend Yield N/A …BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that ...Ikena Oncology, Inc. (NASDAQ:IKNA) fell 11.6% to close at $28.30. Ikena Oncology surged 100% on Friday after the company priced its IPO at $16 per share. Credit Suisse Group AG ...

According to the issued ratings of 4 analysts in the last year, the consensus rating for Ikena Oncology stock is Buy based on the current 4 buy ratings for IKNA. The average twelve-month price prediction for Ikena Oncology is $11.67 with a high price target of $13.00 and a low price target of $11.00. Learn more on IKNA's analyst rating history.

BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, announced ...

Why Ikena Oncology (IKNA) Might Surprise This Earnings Season finance.yahoo.com - May 10 at 11:04 AM: Equities Analysts Offer Predictions for Ikena Oncology, Inc.'s Q1 2023 Earnings (NASDAQ:IKNA) marketbeat.com - May 8 at 1:22 AM: Ikena Oncology (NASDAQ:IKNA) Receives New Coverage from Analysts at HC Wainwright marketbeat.com - May 5 at 11:17 AMBOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...Ikena Oncology, Inc. (NASDAQ:IKNA) announced its earnings results on Wednesday, November, 10th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.02. The business earned $3.75 million during the quarter, compared to analysts' expectations of $2.92 million.Fiscal Q3 2023 ended 9/30/23. Fiscal Q3 2023 ended 9/30/23. Get the latest Ikena Oncology Inc (IKNA) real-time quote, historical performance, charts, and other financial …23 mai 2023 ... Dolar, Borsa, Altın, Eurobond, Bankalar ve Nasdaq Hakkında ... İlahiyatçı Kızlar Celal Şengör'ü "Bir Yaratan" Olduğuna İkna Etmeye Çalışıyorlar.Gainers Chembio Diagnostics, Inc. (NASDAQ:CEMI) shares surged 159.2% to close at $5.34 on Wednesday after the company received a $28.3 million p...Investing.com - Ikena Oncology (NASDAQ: IKNA) divulgou lucro por ação (LPA) de $-0,40 no terceiro trimestre, $0,03 acima da estimativa dos analistas de $-0,43.A receita trimestral foi de $1,19M, contra o consenso de mercado de $2,84M. As ações da Ikena Oncology fecharam em $1,33. Elas caíram -69,07% nos últimos 3 meses e caíram …

NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become ...American International Group Inc. bought a new position in Ikena Oncology, Inc. (NASDAQ:IKNA – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,232 shares of the company’s stock, valued at approximately $67,000. Other hedge funds have also added to or […]BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today ...Oct 1, 2021 · BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three ... Overview Stock Screener Earnings Calendar Sectors Nasdaq | IKNA U.S.: Nasdaq Ikena Oncology Inc. Watch list Set a price target alert After Hours Last Updated: Nov 9, 2023 6:00 p.m. EST...BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...

Check if IKNA Stock has a Buy or Sell Evaluation. IKNA Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Ikena Oncology, Inc. News.Nov 9, 2023 · Ikena Oncology Inc (NASDAQ: IKNA)’s stock price has gone decline by -62.23 in comparison to its previous close of 4.13, however, the company has experienced a -61.58% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology,

3 mai 2022 ... Maude Tessier joins Seismic after serving as Chief Business Officer of Ikena Oncology (Nasdaq: IKNA), a clinical-stage biotech company, where ...BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...Nov 28, 2022 · BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ... BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Ikena Oncology, Inc. (IKNA) NasdaqGM - NasdaqGM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 1.6700 +0.0900 (+5.70%) As of 10:38AM EST. Market open. 1d.Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ...That’s why at the end of this article we will examine companies such as Talos Energy, Inc. (NYSE:TALO), Radius Health Inc (NASDAQ:RDUS), and Ikena Oncology, Inc. (NASDAQ:IKNA) to gather more ...Webull offers Ikena Oncology Inc stock information, including NASDAQ: IKNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKNA stock news, and many more online research tools to help you make informed decisions.BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Ikena Oncology Inc (NASDAQ: IKNA) nominated a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, as its first development candidate in the RAS pathway. The ...

BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

Previous investments include Icosavax (NASDAQ: ICVX), Kymera Therapeutics (NASDAQ ... (NASDAQ: IKNA), Synthekine and Vanqua Bio. Previous to Omega Funds, Paulina ...

KludeIn I Acquisition Corp. Class A Common Stock (INKA) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.Ikena Oncology, Inc. (NASDAQ:IKNA) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's statutory forecasts.The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects.The stock of Ikena Oncology Inc (NASDAQ: IKNA) has increased by 20.81 when compared to last closing price of 1.49.Despite this, the company has seen a gain of 23.29% in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to ...Webull offers Ikena Oncology Inc stock information, including NASDAQ: IKNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKNA stock news, and many more online research tools to help you make informed decisions.30 minutes. No description. Ikena™ is redefining the targeted oncology landscape and envisions a world in which every cancer patient has a cure. We develop therapies that target the underlying mechanisms driving cancer survival and growth.Find the latest Institutional Holdings data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.Financial Results for the Quarter Ended June 30, 2023. As of June 30, 2023, Ikena had $157.3 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ...Find the latest Institutional Holdings data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.

Oct 1, 2021 · BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three ... American International Group Inc. bought a new position in Ikena Oncology, Inc. (NASDAQ:IKNA – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,232 shares of the company’s stock, valued at approximately $67,000. Other hedge funds have also added to or […]Previous investments include Icosavax (NASDAQ: ICVX), Kymera Therapeutics (NASDAQ ... (NASDAQ: IKNA), Synthekine and Vanqua Bio. Previous to Omega Funds, Paulina ...Instagram:https://instagram. how to buy stock in green thumb industrieswhats a funded accountsell xbox 360 for cashcasa amigos owner Is General American Investors Company, Inc. (NYSE:GAM) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the ...Find the latest Institutional Holdings data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com. best platform for scalping optionsbest broker to trade forex Ikena Oncology (NASDAQ:IKNA) appoints a seasoned expert with nearly 15 years of industry experience Jotin Marango, M.D., Ph.D. as CFO and Head of Corporate Development.Most recently he served at ...Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies Stocks trp dividend Nov 7, 2023 · BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ... Dec 17, 2021 · He focuses on private company investments and fundraising for the firm. Mr. Draetta currently serves on the board of Chord Therapeutics and is Chief Financial Officer of Omega Alpha SPAC (NASDAQ ...